Trinity Biotech PLC TRIB
Annual
Quarterly
FY2024 · ended Dec 31, 2024 · Revenue $61.55M, +8.3% YoY · Filed May 16, 2025
Trinity Biotech PLC (TRIB) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2024, which ended Dec 31, 2024, it reported revenue of $61.6 million and a net loss of $31.2 million. Free cash flow was -$4.6 million. As of Dec 31, 2024 it held $5.2 million in cash and investments and $210,000 in total debt.
Revenue
$61.55M
+8.3% vs prior year
Net income
$-31.22M
+15.3% vs prior year
Operating cash flow
$-4.19M
+63.7% vs prior year
Free cash flow
$-4.60M
+62.8% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
374.21M
+4.2% vs prior year
Net cash
$4.96M
FY 2024
Operating margin
-34.4%
FY 2024
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- TRIB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Wicklow
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 888721
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $61.6M | $56.8M | $62.5M | $81.1M | $102.0M |
| Operating income | -$21.2M | -$27.0M | -$19.3M | $3.9M | $82,000 |
| Net income | -$31.2M | -$36.9M | -$43.6M | -$1.9M | -$6.0M |
| Operating cash flow | -$4.2M | -$11.6M | -$921,000 | $13.2M | $23.8M |
| Free cash flow | -$4.6M | -$12.4M | -$2.0M | $11.4M | $20.6M |
| Total assets | $103.3M | $59.4M | $92.1M | $118.9M | $130.4M |
| Total liabilities | $138.5M | $83.4M | $94.3M | $119.2M | $132.6M |
| Stockholders' equity | -$35.2M | -$23.9M | -$2.2M | -$319,000 | -$2.2M |
| Cash and investments | $5.2M | $3.7M | $6.6M | $25.9M | $27.3M |
| Total debt | $210,000 | $210,000 | $210,000 | $83.3M | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 5, 2026 | Oct 2, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Aug 28, 2026 | Aug 28, 2026 |
| 6-K | Current report (foreign issuer) | Aug 17, 2026 | Aug 17, 2026 |
| 6-K | Current report (foreign issuer) | Aug 14, 2026 | Aug 14, 2026 |
All 500 Trinity Biotech PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.